Recor Medical Endorses ESC Hypertension Management Guidelines
The European Society of Cardiology (ESC) recently unveiled updated guidelines for managing high blood pressure during the ESC Congress, highlighting renal denervation as a promising treatment option for those with uncontrolled hypertension.
Palo Alto, California, and Frankfurt am Main, Germany - Recor Medical, Inc. ("Recor"), along with its parent company, Otsuka Medical Devices Co., Ltd., has officially endorsed the ESC's new hypertension management recommendations. This endorsement underscores the key findings presented at the ESC Congress earlier this year, particularly the significance of renal denervation (RDN) for patients dealing with resistant hypertension.
The Impact of Hypertension
Hypertension is a serious health concern that affects more than one billion people worldwide. Often referred to as a silent killer, it frequently goes unnoticed due to its lack of symptoms. Many individuals are unaware of their condition, and despite making lifestyle changes and taking medications, a substantial number still struggle to maintain controlled blood pressure levels. Recor’s cutting-edge Paradise™ Ultrasound Renal Denervation (uRDN) system specifically targets the overactive sympathetic nerves surrounding the renal arteries, providing a solution for hypertensive patients who do not respond adequately to conventional treatments.
Key Developments at the ESC Congress
The updated ESC guidelines, titled "2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension," garnered considerable attention during the congress. These guidelines endorse RDN as a safe and effective treatment option for patients with resistant hypertension, especially those at an increased risk for cardiovascular issues.
Expert Opinions on the New Guidelines
Prof. Dr. Michael Böhm, a distinguished cardiologist and director of Internal Medicine III at Saarland University Hospital, shared his positive outlook on the new recommendations. He remarked, "This guidance marks a significant advancement for patients in need of safe and effective hypertension management options when standard lifestyle changes and medications are insufficient." He emphasized the importance of a multidisciplinary approach to renal denervation management and encouraged thorough discussions about the associated risks and benefits with patients.
Clinical Trials Supporting Efficacy
Recor Medical has successfully conducted three global, independently powered, randomized clinical trials involving over 500 patients with uncontrolled hypertension. These trials—RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II—successfully met their primary objectives, demonstrating significant reductions in blood pressure alongside favorable safety outcomes. The Paradise system has held a CE mark since 2012, and Recor is actively working with the cardiology community throughout Europe to raise awareness and promote the adoption of ultrasound RDN therapy.
Commitment to Hypertension Management
As stated by Recor President and CEO Lara Barghout, "We are excited that the ESC guidelines recognize renal denervation as an effective treatment for uncontrolled hypertension. Addressing this global health challenge is urgent, and we are committed to transforming hypertension management by providing the benefits of our Paradise system to those who need it most."
Company Overview: Recor Medical, Inc.
Recor Medical, located in Palo Alto, California, operates as a subsidiary of Otsuka Medical Devices Co., Ltd. The company is dedicated to innovating hypertension management through the development of the Paradise Ultrasound Renal Denervation system. While still investigational in Japan, this system has received FDA approval in the United States and has obtained the CE mark for broader regulatory acceptance in Europe.
About Otsuka Medical Devices
Otsuka Medical Devices Co., Ltd. is committed to advancing medical technologies that offer novel therapeutic options where existing treatments may fall short. As a subsidiary of Otsuka Holdings Co., Ltd., which is listed on the Tokyo Stock Exchange, Otsuka Medical Devices brings a global perspective to healthcare innovation.
Frequently Asked Questions
What are the new ESC guidelines for hypertension management?
The updated ESC guidelines emphasize the importance of renal denervation as a treatment for uncontrolled hypertension and highlight its efficacy and safety.
Why is renal denervation important for hypertension treatment?
Renal denervation targets sympathetic nerves that contribute to high blood pressure, helping patients who do not respond to lifestyle changes and medication.
What recent studies support the Paradise uRDN system?
Three independent, randomized clinical trials have demonstrated the effectiveness and safety of the Paradise system in managing resistant hypertension.
Who is Recor Medical?
Recor Medical is a medical technology company focused on hypertension treatment, particularly through its innovative ultrasound renal denervation technology.
How does Recor's technology work?
The Paradise system uses ultrasound energy to disrupt overactive renal nerves, aiming to reduce blood pressure and improve patient health outcomes.
